This is the authors' abstract. We don't add key points for this paper.
Introduction: Molecular co‐mutations modulate outcomes in FLT3 ‐mutated AML treated with gilteritinib; real‐world data stratified by DNMT3A co‐mutation status are lacking. Methods We retrospectively analysed 29 adults with R/R FLT3 ‐mutated AML treated at two Italian centres. Sixteen patients with complete molecular profiling were stratified into three subgroups by DNMT3A and NPM1 co‐mutation status. Results Overall response rate was 89.7% (26/29). DNMT3A ‐mutated subgroups showed prolonged OS from gilteritinib initiation versus wild‐type group (median not reached vs. 8.8 months; 12‐month OS 78% vs. 17%). Conclusions These hypothesis‐generating data suggest that DNMT3A co‐mutation status is associated with differential gilteritinib outcomes, supporting comprehensive molecular profiling in FLT3 ‐mutated AML. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Duca et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: